High-grade B-cell Lymphoma
📧 Sign up to get email alerts when something new happens for High-grade B-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS other · 2025-04-24Clinical Trial Update: DALY II USA/ MB-CART2019.1 for DLBCL [Phase 2]
Miltenyi Biomedicine's MB-CART2019.1 (DALY II) is in Phase 2 for refractory/relapsed B-cell lymphomas, including Diffuse Large B-Cell Lympho…
-
CLINICAL_TRIALS research · 2025-04-09Clinical Trial Update: Study of Loncastuximab Tesirine in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or High-Grade B-Cell Lymphoma (HGBCL) Following CAR-T Therapy Failure [Phase 2]
A Phase 2 clinical trial evaluating loncastuximab tesirine in patients with relapsed or refractory diffuse large B-cell lymphoma or high-gra…
-
CLINICAL_TRIALS research · 2025-03-27Clinical Trial Update: Epcoritamab-CAR T Cells for Large B-cell Lymphomas [Phase 2]
Phase 2 clinical trial evaluating epcoritamab-CAR T cells for large B-cell lymphomas, currently recruiting.
-
CLINICAL_TRIALS research · 2025-02-11Clinical Trial Update: Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL [Phase 2]
A Phase 2 clinical trial evaluating Relmacabtagene autoleucel as second-line therapy for adults with aggressive B-cell non-Hodgkin lymphomas…
-
CLINICAL_TRIALS trial_result · 2025-01-28Clinical Trial Update: Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma [Phase 2]
Phase 2 study evaluating anakinra to reduce CAR-T–related toxicity in patients with relapsed or refractory diffuse large B-cell lymphoma has…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-01-28Clinical Trial Update: Immunotherapy in Lymphoma
An ongoing immunotherapy trial for relapsed or refractory B-cell lymphomas is currently recruiting. The study targets high-grade B-cell lymp…
-
CLINICAL_TRIALS trial_result · 2025-01-14Clinical Trial Update: Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma [Phase 2]
A Phase 2 clinical trial update indicates Sepantronium bromide is being studied for high-grade B-cell lymphomas, with the study currently ac…
-
CLINICAL_TRIALS research · 2024-10-15Clinical Trial Update: Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse [Phase 2]
Phase 2 trial evaluating Golcadomide after CAR T-cell therapy in adults with relapsed/refractory aggressive diffuse large B-cell lymphoma an…
-
CLINICAL_TRIALS trial_result · 2024-08-13Clinical Trial Update: First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas [Phase 1, Phase 2]
First-in-human study of GEN3009 in relapsed or refractory B-cell non-Hodgkin lymphomas was terminated, with results posted thereafter.
-
CLINICAL_TRIALS trial_result · 2024-08-12Clinical Trial Update: A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL) [Phase 1, Phase 2]
A multicentre, open-label Phase 1/2 trial is evaluating frontline regimens R-CHOP/Pola-RCHP and Glofitamab in younger patients with high-ris…
-
CLINICAL_TRIALS research · 2024-07-22Clinical Trial Update: Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL [Phase 2]
Phase 2 clinical trial evaluating salvage therapy that includes epcoritamab (Epcor) followed by autologous stem cell transplant and epcorita…
-
CLINICAL_TRIALS trial_result · 2024-07-09Clinical Trial Update: FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL [Phase 1]
Phase 1 trial results for FT596 CAR-T cells with Rituximab as relapse prevention after autologous HSCT in non-Hodgkin lymphoma were posted, …
-
CLINICAL_TRIALS trial_result · 2024-07-09Clinical Trial Update: Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas [Phase 1]
Phase 1 trial evaluating copanlisib with dose-adjusted EPOCH-R in relapsed and refractory Burkitt lymphoma and other high-grade B-cell lymph…
-
CLINICAL_TRIALS trial_result · 2024-02-14Clinical Trial Update: DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBL [Phase 2]
Phase 2 trial evaluating DA-EPOCH-R induction followed by nivolumab consolidation in newly diagnosed high-grade B-cell lymphoma with MYC, BC…
-
CLINICAL_TRIALS trial_result · 2023-06-07Clinical Trial Update: Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial evaluating mogamulizumab in combination with pembrolizumab for relapsed or refractory diffuse large B-cell lymphoma and rela…
-
CLINICAL_TRIALS trial_result · 2022-10-25Clinical Trial Update: Treatment for Advanced B-Cell Lymphoma [Phase 2]
Phase 2 clinical trial completed for treatment of advanced B-cell lymphoma, including diffuse large B-cell lymphoma and Burkitt's lymphoma.
-
CLINICAL_TRIALS trial_result · 2022-04-14Clinical Trial Update: Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma [Phase 1, Phase 2]
Clinical trial update investigating toripalimab in combination with rituximab followed by R-CHOP for elderly patients with untreated diffuse…
-
CLINICAL_TRIALS trial_result · 2022-01-26Clinical Trial Update: DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma [Phase 2]
Phase 2 protocol update for DLCL002 in high-risk aggressive B-cell lymphoma patients.
-
CLINICAL_TRIALS trial_result · 2021-11-23Clinical Trial Update: Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma [Phase 1, Phase 2]
This document reports the completion of a Phase 1/2 trial evaluating axicabtagene ciloleucel (KTE-C19) for adults with refractory or relapse…
-
CLINICAL_TRIALS trial_result · 2021-09-20Clinical Trial Update: Phase II Trial of Tirelizumab Combined With R2-ICE Regimen in the Treatment of rrDLBCL/HGBL [Phase 2]
Phase II trial update examining tirelizumab with the R2-ICE regimen for relapsed/refractory diffuse large B-cell lymphoma and high-grade B-c…
-
CLINICAL_TRIALS trial_result · 2021-03-15Clinical Trial Update: Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL [Phase 1, Phase 2]
Phase 1/2 trial evaluating tislelizumab plus lenalidomide in refractory/relapsed elderly patients with various aggressive B-cell lymphomas, …
-
CLINICAL_TRIALS withdrawal · 2017-05-19Clinical Trial Update: Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma [Phase 2]
The Phase 2 trial of Brentuximab Vedotin, Bendamustine, and Rituximab for relapsed or refractory B-cell non-Hodgkin lymphoma has been withdr…
-
CLINICAL_TRIALS research · 2017-02-24Clinical Trial Update: Retrospective Analysis of Rituximab-containing Immunochemotherapy for Burkitt's or Burkitt-like Lymphoma in Adults
This clinical trial update presents a retrospective analysis of rituximab-containing immunochemotherapy for adults with Burkitt lymphoma or …